Turn­ing Point looks to chal­lenge Pfiz­er, Roche with new ear­ly da­ta for lead lung can­cer drug

Turn­ing Point Ther­a­peu­tics shared a Phase I/II up­date for its lead drug can­di­date re­potrec­tinib, but in­vestors said they were ex­pect­ing slight­ly bet­ter.

In 71 to­tal TKI-naive pa­tients, the con­firmed ob­jec­tive re­sponse rate (cORR) to re­potrec­tinib, al­so known as TPX-0005, was 79%, down from an ear­li­er re­port of a 91% ORR in 22 pa­tients. In ad­di­tion, four pa­tients achieved com­plete re­sponse, Turn­ing Point said in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER